Table 4

Effects of CMR-RVpGLS on 5-year major adverse cardiac events in patients with stage C or D heart failure with non-ischaemic dilated cardiomyopathy in each subgroup by multivariable Cox model

CMR-RVpGLSHR (95% CI)P valueP for interaction
Age (years)0.522
 ≤561.07 (0.92 to 1.25)0.353
 >561.25 (1.00 to 1.57)0.047
Sex0.359
 Female0.97 (0.78 to 1.20)0.763
 Male1.19 (1.03 to 1.38)0.017
BMI0.441
 ≤261.12 (0.98 to 1.29)0.089
 >261.22 (0.93 to 1.59)0.153
Hypertension0.144
 No1.08 (0.94 to 1.25)0.253
 Yes1.31 (0.99 to 1.73)0.058
Diabetes mellitus0.240
 No1.21 (1.03 to 1.42)0.018
 Yes1.02 (0.86 to 1.22)0.784
LBBB on EKG0.279
 No1.11 (0.97 to 1.27)0.118
 Yes1.27 (0.92 to 1.75)0.142
  • *Adjusted for age, sex, BMI, hypertension, diabetes mellitus, LBBB on EKG and CMR LVLGE except the subgroup variable.

  • BMI, body mass index; CMR, cardiac magnetic resonance; LBBB, left bundle branch block; LVLGE, left ventricular late gadolinium enhancement; RVpGLS, right ventricular peak global longitudinal strain.